Silence Signs Takeda Deal And Sets Sights On US

Business As Usual After Abrupt CEO Exit

The resignation of David Horn Solomon last month was a setback for Silence but the company believes it will benefit from the growing prominence given to RNAi technology.

Binoculars_Manhattan
Silence eyes opportunities stateside • Source: Shutterstock

Despite the surprise departure of CEO David Horn Solomon at the end of 2019, Silence Therapeutics PLC of the UK says it is in good shape and has unveiled a deal with Takeda Pharmaceutical Co. Ltd. as well as plans to set up a US subsidiary.

The pact with Takeda, worth “single-digit million dollars of research funding," will see the Japanese major use the London-based gene...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Merck’s Winrevair Approved For PAH In Europe As Initial US Launch Progresses

 
• By 

Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.

BioMarin Recruits Amgen R&D’s Friberg, Roche Dealmaker Sabry To Leadership Team

 
• By 

The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.

Gene Therapy Patient Pipeline Builds, But Slowly, In Q2

 

Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area. 

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.